Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic NSCLC

NCT00890825 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00890825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00890825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic NSCLC
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
April 20, 2009
Completion date
November 2, 2016
Enrollment
88 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer